Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.40 |
| ▸ | JUN | P05412 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.38 |
| ▸ | VCP | P55072 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2016776 | 0.91 | EGFR (0.48) | EGFRKCNH2GRIN2BJUNCDK2 | |
| SCHEMBL2016080 | 0.88 | EGFR (0.49) | EGFRKCNH2GRIN2BJUNCDK2 | |
| SCHEMBL2019168 | 0.88 | EGFR (0.47) | EGFRKCNH2 | |
| SCHEMBL2020110 | 0.87 | EGFR (0.48) | EGFRKCNH2GRIN2BJUNCDK2 | |
| SCHEMBL2019799 | 0.87 | EGFR (0.48) | EGFRKCNH2GRIN2BJUNCDK2 | |
| SCHEMBL2021867 | 0.86 | EGFR (0.48) | EGFRKCNH2GRIN2BCDK2VCP | |
| SCHEMBL2017752 | 0.85 | EGFR (0.48) | EGFRKCNH2GRIN2BCDK2VCP | |
| SCHEMBL2017372 | 0.85 | EGFR (0.50) | EGFRKCNH2GRIN2B | |
| SCHEMBL2020150 | 0.85 | EGFR (0.49) | EGFRKCNH2GRIN2BCDK2VCP | |
| SCHEMBL2023143 | 0.84 | GRIN2B (0.59) | EGFRKCNH2GRIN2BJUNCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563567-B2 | Substituted heterocyclic compounds | ARQULE, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-8563567-B2 | Substituted heterocyclic compounds | ARQULE, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-8563567-B2 | Substituted heterocyclic compounds | ARQULE, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| WO-2011082266-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | ARQULE, INC. (US) | 2011-07-07 | — | — | WO | disclosed |
| US-20110160237-A1 | Substituted Heterocyclic Compounds | ARQULE, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160237-A1 | Substituted Heterocyclic Compounds | ARQULE, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160237-A1 | Substituted Heterocyclic Compounds | ARQULE, INC. (US) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160237-A1 | Substituted Heterocyclic Compounds | MKI67, CCNC, NQO1 | EGFR 220/4885KCNH2 4116/4885GRIN2B 4135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.